EUS-Guided Radiofrequency Ablation as a Minimally Invasive Treatment for Insulinomas—A Single-Center Experience
Authors' conclusion
EUS-RFA appears to provide complete symptom resolution and demonstrates a favorable safety profile compared to conventional surgery. However, the long-term efficacy of EUS-RFA remains to be determined.
Study context
- Population
- Patients with suspected insulinoma (positive fasting test and imaging), biopsy-proven pancreatic neuroendocrine neoplasms (pNENs) with Ki-67 <10% and <25 mm, single tertiary centre, 2022–2025; mean age 60.1 years, 53% male
- Participants
- 17 patients
- Outcome
- Clinical success (symptom improvement with documented increase in blood glucose) and safety
- Follow-up
- Mean 15.5 months
Methodological detailssingle-centre, All patients hospitalized for 24 hours
- Single-centre
- All patients hospitalized for 24 hours
Main finding
As reported in the abstract
Overall clinical success
EUS-RFA
100%
17 of 17
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Normoglycemia after a single EUS-RFA session | EUS-RFA 64.7% |
- Normoglycemia after a single EUS-RFA session — Required a second EUS-RFA
- 6 patients (35.3%)
Safety
- Adverse events in 23 procedures
- 4 (17.4%)
- Mild adverse events
- 2
- Moderate adverse events
- 2 (8.7%)
- Per procedure
Original publication
EUS-Guided Radiofrequency Ablation as a Minimally Invasive Treatment for Insulinomas—A Single-Center Experience. J Clin Endocrinol Metab. Published 22 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →